Ocugen (OCGN) News Today $0.74 +0.02 (+3.40%) Closing price 04:00 PM EasternExtended Trading$0.73 -0.01 (-0.95%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ocugen Advances OCU200 Clinical Trial Amid Promising Safety ResultsMarch 19, 2025 | msn.comOcugen says DSMB approves dosing Cohort 2 in OCU200 clinical trialMarch 18, 2025 | markets.businessinsider.comData and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular EdemaMarch 18, 2025 | globenewswire.comHC Wainwright Forecasts Ocugen's Q1 Earnings (NASDAQ:OCGN)Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Ocugen in a research note issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.05) per share for the quarter, dMarch 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for Ocugen Q1 EarningsOcugen, Inc. (NASDAQ:OCGN - Free Report) - Investment analysts at HC Wainwright cut their Q1 2025 EPS estimates for Ocugen in a research report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.05) per share for the quarter,March 10, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Ocugen FY2029 Earnings?Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Ocugen in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings peMarch 8, 2025 | marketbeat.comChardan Capital Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock PriceChardan Capital lifted their price target on Ocugen from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday.March 7, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Ocugen in a research report on Thursday.March 7, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Announces Quarterly Earnings Results, Hits EstimatesOcugen (NASDAQ:OCGN - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same period in the previous year, the firm earned ($0.03) EPS.March 6, 2025 | marketbeat.comOcugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your BehalfMarch 6, 2025 | financialpost.comOcugen, Inc. (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comOcugen reports Q4 EPS (5c), consensus (5c)March 6, 2025 | markets.businessinsider.comOcugen (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comOcugen Reports Progress in Gene Therapy TrialsMarch 5, 2025 | tipranks.comOcugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial ResultsMarch 5, 2025 | globenewswire.comNoble Financial Sticks to Its Buy Rating for Ocugen (OCGN)March 4, 2025 | markets.businessinsider.comOcugen announces EC provided position opinion from EMA’s CAT for OCU410March 3, 2025 | markets.businessinsider.comGrabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)March 3, 2025 | financialpost.comAnalysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)March 1, 2025 | markets.businessinsider.comOcugen aligns with FDA on confirmatory study for OCU410STFebruary 27, 2025 | msn.comOcugen reports FDA alignment on Phase 2/3 OCU410ST trial in Stargardt diseaseFebruary 27, 2025 | markets.businessinsider.comOcugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt DiseaseFebruary 27, 2025 | globenewswire.comOcugen (OCGN) Expected to Announce Earnings on WednesdayOcugen (NASDAQ:OCGN) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669102)February 26, 2025 | marketbeat.comGrabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)February 24, 2025 | financialpost.comOcugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 21, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for Ocugen FY2024 Earnings?Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Ocugen in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company wiFebruary 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Ocugen FY2024 Earnings?Ocugen, Inc. (NASDAQ:OCGN - Free Report) - HC Wainwright increased their FY2024 earnings per share estimates for Ocugen in a research note issued on Thursday, February 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.17) per share for the year, up frFebruary 17, 2025 | marketbeat.comOcugen price target raised to $8 from $7 at H.C. WainwrightFebruary 14, 2025 | markets.businessinsider.comOcugen shares rise as H.C. Wainwright lifts price target to $8February 14, 2025 | msn.comWhy Ocugen (OCGN) Is Advancing TodayFebruary 14, 2025 | msn.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $6.00 price target on shares of Ocugen in a report on Thursday.February 13, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Given New $8.00 Price Target at HC WainwrightHC Wainwright upped their price target on shares of Ocugen from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Thursday.February 13, 2025 | marketbeat.comOcugen announces dosing completion in Phase 2 ArMaDa clinical trialFebruary 12, 2025 | markets.businessinsider.comOcugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationFebruary 12, 2025 | globenewswire.comOcugen gets positive EU opinion for ATMP classification for OCU400February 3, 2025 | seekingalpha.comEuropean Commission nods at Ocugen's gene therapyFebruary 3, 2025 | msn.comOcugen Gets Positive Opinion For OCU400 Advanced Therapy Medicinal Product ClassificationFebruary 3, 2025 | markets.businessinsider.comOcugen’s OCU400 granted positive opinion by EMA in retinitis pigmentosaFebruary 3, 2025 | markets.businessinsider.comOcugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis PigmentosaFebruary 3, 2025 | globenewswire.comOcugen files to sell 57.54M shares of common stock for holdersFebruary 1, 2025 | markets.businessinsider.comOcugen announces IND in effect after FDA reviewJanuary 28, 2025 | markets.businessinsider.comOcugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19January 27, 2025 | globenewswire.comOcugen’s Promising Pipeline and Strategic Advancements Bolster Buy RatingJanuary 24, 2025 | markets.businessinsider.comOcugen's (OCGN) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and set a $6.00 target price on shares of Ocugen in a research report on Thursday.January 24, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $6.00 price objective on shares of Ocugen in a report on Thursday.January 23, 2025 | marketbeat.comBreakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialJanuary 18, 2025 | msn.comBreakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaJanuary 17, 2025 | msn.comOcugen announces first patient dosed in Phase 1 OCU200 trial for DMEJanuary 16, 2025 | markets.businessinsider.comOcugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular EdemaJanuary 16, 2025 | globenewswire.com Remove Ads Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address OCGN Media Mentions By Week OCGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼1.050.89▲Average Medical News Sentiment OCGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼15▲OCGN Articles Average Week Remove Ads Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Cronos Group News ArriVent BioPharma News Organogenesis News CorMedix News GH Research News CureVac News Immunome News Nuvation Bio News Arbutus Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCGN Stock Free OCGN Stock Alerts